Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations
Demerger: Natco Pharma shares gained nearly 4 per cent in trade on Friday ahead of next week's board meeting to consider a demerger proposal
In the past four trading days, the stock price of Natco Pharma has surged 10 per cent after the company announced the launch of Pomalidomide Capsules (generic of Pomalyst) in the US market.
The buying on the counter came after Natco Pharma, along with Breckenridge Pharmaceutical, launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene, in the US market.
At 01:13 PM on Tuesday; Nifty Pharma index, the top gainer among sectoral indices, was up 0.2 per cent, as compared to 1.1 per cent decline in the Nifty 50.
The buying on the counter came after Natco Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India
Stocks to watch today, Friday, February 13, 2026: Market participants will keep an eye on SpiceJet, Coal India, Biocon, Infosys, Mishra Dhatu Nigam, Indraprastha Gas share prices today
Among smallcaps - Natco Pharma, Neuland Laboratories, Inox India, Welspun Living and GE Shipping shares have witnessed the formation of 'Double Bottom' pattern on the technical charts.
Natco Pharma, in a regulatory filing, has informed the exchanges that the credit rating agency ICRA Limited has reaffirmed and assigned credit ratings for Natco Pharma's various debt instruments.
Natco Pharma shares fell 2 per cent as it received seven observations in the Form-483 from the US Food and Drug Administration
Among the Nifty 500 constituents, Tejas Networks (down 56 per cent), Praj Industries (down 54 per cent), and Vedant Fashions (down 52 per cent) were among the worst hit
The buying on the counter came after the Delhi High Court dismissed an appeal by F. Hoffmann-La Roche AG, removing the last legal hurdle for Natco Pharma to launch a generic version of Risdiplam
The court upheld a previous order denying Roche's injunction plea, citing public interest and affordability in treatment for spinal muscular atrophy patients